Freeze and fight: new combo therapy targets melanoma

NCT ID NCT03949153

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new approach for stage IIIB/C melanoma, the deadliest form of skin cancer. Nineteen participants received a single infusion of the immunotherapy drug nivolumab, followed by cryotherapy (freezing) of a cancerous lymph node, and then an injection of another immunotherapy drug, ipilimumab, directly into the frozen area. The goal was to see if this combination was feasible and could trigger a stronger immune response against the cancer while potentially reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If successful, this approach could offer a new way to treat advanced melanoma by combining tumor destruction with targeted immunotherapy, potentially improving outcomes and reducing side effects.
What could go wrong
This was a small, early-phase proof-of-concept study with only 19 participants, so results may not apply broadly. The combination also carries risks of immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinique Dermatologique/Radiologie Interventionnelle/Urologie/Gynécologie-CHU de Strasbourg/ICANS

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.